PharmaCyte Biotech reaches cooperation agreement with Iroquois Capital
Company appoints five new independent directors to reconstituted board
Company appoints five new independent directors to reconstituted board
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
Investment in response to increased demand for North American-based chemistry services
The company has reported total income of Rs. 1607.85 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 317.45 crores during the period ended June 30, 2022
The company has reported total income of Rs. 264.09 crores during the period ended June 30, 2022.
Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply
Health resources – both human and material are precious assets to the society and a robust health care administration and management system ensures their effective utilization: Dr Bharati Pravin Pawar
Steps afoot to make RRIH & RRIUM as a Centres of Excellence for Allergic Disorder and for Regimental Therapy respectively
Subscribe To Our Newsletter & Stay Updated